Esketamine

證據等級: L5

預測適應症: 2 個

Esketamine: From Treatment-Resistant Depression to Agoraphobia

One-Sentence Summary

Esketamine (S-ketamine) is the S-enantiomer of ketamine, approved internationally as an intranasal therapy for treatment-resistant depression (TRD) and major depressive disorder with acute suicidal ideation. The TxGNN model predicts it may be effective for Agoraphobia, with 0 clinical trials and 1 publication currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Treatment-resistant depression (no Taiwan registration; based on global approval context)
Predicted New Indication	Agoraphobia
TxGNN Prediction Score	99.57%
Evidence Level	L4
Taiwan Market Status	✗ Not marketed
Number of Licenses	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known information, esketamine is an NMDA (N-methyl-D-aspartate) receptor antagonist — the more pharmacologically active S-enantiomer of racemic ketamine. Its efficacy in treatment-resistant depression has been established through the intranasal formulation (Spravato®), working by rapidly modulating synaptic glutamate signaling, which subsequently promotes synaptic plasticity via BDNF/TrkB pathway remodeling. This “rapid-acting antidepressant” mechanism is mechanistically distinct from conventional monoaminergic antidepressants.

Agoraphobia, frequently comorbid with panic disorder, involves dysregulation of the amygdala–prefrontal cortex glutamate circuit implicated in fear conditioning and fear extinction failure. NMDA receptor antagonism may theoretically facilitate fear memory extinction and remodel fear-encoding circuits — a biologically plausible but as yet unvalidated pathway for this indication.

However, this mechanistic bridge remains indirect. Esketamine’s demonstrated efficacy in TRD has not been formally extrapolated to anxiety spectrum disorders, and no dedicated clinical trials for agoraphobia have been identified. The TxGNN prediction captures a genuine glutamatergic hypothesis, but it requires independent preclinical validation before any clinical development pathway can be considered.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
33424664	2020	Narrative Review	Frontiers in Psychiatry	Broad review of approved and off-label pharmacotherapy for panic disorder, GAD, and social anxiety disorder; highlights the relative lack of novel anxiolytic agents under investigation; does not report esketamine-specific data for agoraphobia, but contextualises the unmet need in anxiety pharmacotherapy

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The only supporting evidence is a general narrative review of anxiety disorder pharmacotherapy; no clinical trials or direct empirical studies investigating esketamine specifically for agoraphobia have been identified, and the mechanistic rationale — while biologically coherent through NMDA-glutamate pathways — remains indirect, unvalidated, and not yet bridged from TRD to anxiety spectrum disorders.

To proceed, the following is needed:

Preclinical data in fear extinction or agoraphobia-relevant animal models to validate the NMDA antagonism hypothesis in this context
Full MOA profile from DrugBank (currently a data gap) to strengthen mechanistic analysis
Package insert warnings and contraindications (TFDA/FDA labeling) — currently blocking S1 safety screening
Drug-drug interaction profile for esketamine
Bridging literature review of racemic ketamine in panic disorder or agoraphobia as an indirect comparator
Feasibility assessment of Taiwan regulatory pathway if preclinical evidence supports further development
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.